Research Community Events

Invited Guest Lecturers

Jonathan M. Kurie, M.D
‘Transcriptional control of Golgi functions in tumor cells drives EMT and metastasis’
Professor, Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center, Houston, TX

Lauren Averett Byers, MD
Targeting the proteome in Small Cell Lung Cancer - Emergence of PARP, CHK1, and other DDR inhibitors’
Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center, Houston, TX

Paul Bunn, MD
’Rational combinations for upfront EGFR mutant lung adenocarcinomas’
Professor, Division of Medical Oncology
James Dudley Chair in Lung Cancer Research
University of Colorado

Alice Shaw, MD, PhD
Director, Center for Thoracic Cancers, Massachusetts General Hospital
Paula O’Keeffe Endowed Chair in Thoracic Oncology, Massachusetts General Hospital
Co-Leader, Lung Cancer Program, Dana Farber/Harvard Cancer Center

Charles Swanton, FRCP BSc PhD
’Tracking Lung Cancer Evolution: Insights from the TRACERx Program’
Chair, Personalised Cancer Medicine, University College London
Co-Director CR-UK UCL/Manchester Lung Cancer Centre of Excellence 
Translational Cancer Therapeutics Laboratory
Francis Crick Institute, London, UK

Brendon M. Stiles, MD
Associate Attending, Cardiothoracic Surgery
NewYork-Presbyterian Hospital, Weill Cornell Medical College, Cornell University

Marty W. Mayo, PhD
Associate Professor, Biochemistry and Molecular Genetics
University of Virginia, School of Medicine

MSK Community Work in Progress Lectures

November 18, 2016
Yuan Liu, MD, PhD
Biochemist, Memorial Hospital Research Labs, David Jones Lab

November 4 , 2016
Alex Drilon, MD
Thoracic Oncology Service
Romel Somwar, PhD
Department of Pathology
“Identifying Mechanisms of Acquired Resistance to RET Inhibition in RET-Rearranged Lung Cancers”

October 14 , 2016
Natasha Rekhtman, MD, PhD
Department of Pathology
‘Genomic analysis of lung neuroendocrine tumors in the context of detailed histological, immunohistochemical and clinical correlation’

September 30, 2016
Paul Paik, MD
Clinical Director, Thoracic Oncology Service
‘A Phase 2 Study of MLN0128 in Patients with Advanced Squamous Cell Lung Cancers Harboring NFE2L2 and KEAP1 Mutations’

September 9 ,2016
Benjamin Lok, MD
Molecular Pharmacology Program, Rudin Lab
‘Strategies to predict response to and maximize PARP inhibitor therapy for small cell lung cancer’

August 19, 2016
Hans Guido Wendel, MD
Member, Cancer Biology & Genetics Program, Center for Stem Cell Biology
J.T. Poirier, PhD
Thoracic Oncology Service, Molecular Pharmacology Program, Rudin Lab
‘eIF4A is a New Therapeutic Target in Small Cell Lung Cancer’

July 22, 2016
J.T. Poirier, PhD
Thoracic Oncology Service, Molecular Pharmacology Program, Rudin Lab
Jason Lewis, PhD
Chief, Radiochemistry and Imaging Sciences Services, Department of Radiology
‘Preclinical development of a DLL3-targeted theranostic for high-grade neuroendocrine lung cancers’

July 8, 2016
Eli Amin, PhD
Memorial Hospital Research Labs, David Jones Lab
‘ADAR mediated RNA editing in Lung Adenocarcinoma’

June 10, 2016
Joana DeCampos Vidigal, PhD
Cancer Biology & Genetics Program, Ventura Lab
‘Improving CRISPR-Cas9 tools for somatic genome editing’

May 20, 2016
Daniel Heller, PhD
Member, Molecular Pharmacology Program
‘Targeted Drug Delivery to the Tumor Microenvironment’

29 April 2016
Prasad Adusumilli, MD
Deputy Chief, Translational and Clinical Research, Thoracic Surgery
‘CAR T-cell therapy for lung adenocarcinoma’

April 15, 2016
David R. Jones, MD
Director, DCLCR; Chief, Thoracic Surgery, Department of Surgery
‘The role of BRMS1 in p53 mutant lung adenocarcinoma’

April 8, 2016
Bob T. Li, MD
Thoracic Oncology Service
‘Circulating Tumor DNA in Lung Cancers - The State of the Art and the Future’

March 18, 2016
Eric Gardner, PharmD
Rudin Lab, Molecular Pharmacology Program
‘Chemo-sensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis”

January 22, 2016
Charles Rudin, MD, PhD
Director, DCLCR; Chief, Thoracic Oncology Service; Member, Molecular Pharmacology Program
‘New Targets in Small Cell Lung Cancer’